Research AppraisalRandomised Controlled Trial

Mycoelectronics: Bioprinted living fungal bioelectronics for artificial sensation

Proceedings of the National Academy of Sciences of the United States of AmericaCai, Yulu, Yuan, Hang, Ronders, Caleb et al.30 June 2026DOI

Clinical Snapshot

50CEBM
Evidence: WeakRandomised Controlled Trial

PICO Framework

P — PopulationProof-of-concept platform study; no human patient population enrolled. Relevant end-users include humans and robotic systems requiring wearable or environmental thermal sensing
I — InterventionAdditive bioprinting of living fungal mycelium (Mycoelectronics) onto stretchable electronic substrates to create a thermoresponsive living sensory device
C — ComparatorImplicit comparison with existing eukaryote-based biohybrid electronic systems and conventional synthetic soft-electronic sensors; no formal head-to-head comparator arm reported
O — OutcomesPrimary: thermal responsiveness (electrical conductivity changes in response to heat stimuli, mediated by vacuole remodeling and ionic transport). Secondary: response speed, self-healing capacity after mechanical damage, bioprintability/scalability, stability under ambient conditions, and proof-of-concept application in environmental monitoring, agricultural sensing, and wearable human/robotic sensing

Bottom Line

This PNAS paper introduces 'Mycoelectronics' — a proof-of-concept platform in which living fungal mycelium networks are bioprinted onto stretchable electronic substrates to create a thermoresponsive sensory device. The biological mechanism — heat-induced vacuole remodeling altering ionic conductivity — is a genuinely novel contribution to the biohybrid electronics field. The self-healing capability and ambient-condition stability address real limitations of prior eukaryote-based systems. However, clinicians and translational researchers should interpret these findings with appropriate caution. The study is a bench-level demonstration with no quantitative performance benchmarking, no statistical analysis reported in the abstract, no human or animal data, and no biosafety evaluation. The technology readiness level is low (approximately TRL 2–3). Significant translational barriers remain, including long-term viability of living sensors in clinical environments, biosafety for immunocompromised users, and regulatory pathways. In the Australian context, TGA and potentially OGTR oversight would be required before any clinical application. This is an intellectually compelling early-stage innovation warranting monitoring by clinicians in wearable health technology, rehabilitation engineering, and precision agriculture, but it is many years from clinical deployment.

Evidence: Weak

Key Findings

  • P Value: Not reported

  • Effect Size: Not reported in abstract; quantitative conductivity change magnitudes not provided

  • Primary Outcome: Demonstration of thermoresponsive electrical conductivity changes in bioprinted living fungal mycelium networks, mediated by heat-induced vacuole remodeling and ionic transport modulation

  • Nnt Or Sensitivity: Not applicable to this proof-of-concept study; no sensitivity, specificity, NNT, or hazard ratio reported. Sensor response speed described qualitatively as 'rapid' but no numerical response time (e.g., milliseconds) provided in abstract

  • Confidence Interval: Not reported

Clinical Application

Feasibility in clinical or real-world settings is unestablished. Key barriers include: maintenance of living fungal cultures in non-laboratory environments, biosafety certification for skin-contact fungal devices, sterilisation incompatibility of living organisms, regulatory approval pathways for biohybrid medical devices, and manufacturing scale-up from bench to commercial production. The bioprinting approach is a positive feasibility signal for scalability. In the Australian context, any wearable device incorporating living fungal organisms would require TGA evaluation under the Therapeutic Goods Act 1989 as a medical device, with specific consideration of biological safety under ISO 10993. The use of living microorganisms in consumer or clinical products may also engage the Office of the Gene Technology Regulator (OGTR) if genetic modification is involved. The RACGP has no current guidelines relevant to fungal bioelectronics. Potential agricultural monitoring applications are relevant to Australian precision agriculture and could engage the Australian Pesticides and Veterinary Medicines Authority (APVMA) or state biosecurity frameworks if living fungal material is deployed in field settings. PBS listing is not applicable at this stage. Australian researchers at institutions such as the ARC Centre of Excellence in Synthetic Biology may find this work relevant to national synthetic biology strategy. Not yet applicable to any defined clinical population. Potential future populations include patients requiring continuous wearable thermal monitoring (e.g., peripheral vascular disease, diabetic neuropathy, burn wound management), robotic prosthetics requiring artificial sensation, and precision agriculture operators. All applications remain speculative at current technology readiness level.

Abstract

The intelligence of the human biological system is enabled by the highly distributed sensing receptors on soft skin that can distinguish various stimulations or environmental cues, thus establishing the fundamental logic of sensing and physiological regulation or response. To replicate biological perception, biohybrid systems integrating living organisms with electronics have been developed to sense environmental cues. However, current eukaryote-based biohybrids face slow growth, strict culture needs, and short lifespans, limiting real-world use. Here, we introduce fungi-based printable "Mycoelectronics" which are created by additive bioprinting of living fungal mycelium networks onto stretchable electronics, as a practical living thermoresponsive sensory platform. This mycoelectronics approach leverages fung's capabilities for rapid biological responsiveness, cultivability with exponential growth, stability and self-healing in ambient conditions, bioprintability for scalable manufacturing, and mechanical flexibility for seamless integration with soft electronics. We show that the thermal responsiveness of the fungal network arises from intrinsic cellular processes-specifically, heat-induced vacuole remodeling and fusion, which modulate ionic transport and thus the electrical conductivity of the mycelial cells and networks, enabling a rapid response. By bridging the gap between cell biology and soft electronics, the mycoelectronics device, with a living mycelial network, functions as a thermal sensation system with rapid response and intrinsic self-healing properties, autonomously restoring sensing capabilities after damage and establishing sensing pathways in hard-to-reach locations. Application demonstrations in environmental and agricultural monitoring and wearable sensing systems for humans and robots highlight the versatility of this living fungal sensor platform, suggesting promising opportunities in healthcare and the environment.

References

  1. 1.Cai, Y., Yuan, H., Ronders, C., Mottini, V., Singh, K., Xing, L., Singh, I., Fu, D., Zhao, K., Heller, L., Nguyen, K., Waller, B., Wang, T., Bonito, G., & Li, J. (2026). Mycoelectronics: Bioprinted living fungal bioelectronics for artificial sensation. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.2530456123
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service